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Abstract The objective was to compare three score sys-
tems, pneumonia severity index (PSI), the Confusion-Urea-
Respiratory Rate-Blood pressure-65 (CURB-65), and severe
community-acquired pneumonia (SCAP), for prediction of
the outcomes in a cohort of patients with community-
acquired (CAP) and healthcare-associated pneumonia
(HCAP). Large multi-center, prospective, observational
study was conducted in 55 hospitals. HCAP patients were
included in the high classes of CURB-65, PSI and SCAP
scores have a mortality rate higher than that of CAP patients.
HCAP patients included in the low class of the three severity
rules have a significantly higher incidence of adverse events,
including development of septic shock, transfer into an ICU,
and death (p \ 0.01). At multivariate Cox regression anal-
ysis, inclusion in the severe classes of PSI, CURB-65, or
SCAP scores and receipt of an empirical therapy not
adherent to international guidelines prove to be risk factors
independently associated with poor outcome. PSI, CURB-
65, and SCAP score have a good performance in patients
with CAP but are less useful in patients with HCAP, espe-
cially in patients classified in the low-risk classes.
Keywords Community-acquired pneumonia 
Healthcare-associated pneumonia  PSI  CURB 65
Introduction
Traditionally, pneumonia occurring in patients living in the
community has been categorized as community-acquired
pneumonia (CAP). However, the designation of healthcare-
associated pneumonia (HCAP) has been recently intro-
duced to include a population of nursing-home residents,
patients receiving home- or hospital-based intravenous
therapy, undergoing dialysis, or with a history of recent
hospitalization [1]. Patients with HCAP have a more severe
disease with longer hospital stay and higher mortality rates
[1, 2], and inclusion criteria for HCAP have been associ-
ated with an increased risk for multidrug-resistant (MDR)
pathogens [3].
The two most widely used predictive score systems for
CAP are the pneumonia severity index (PSI) [4] and the
Confusion-Urea-Respiratory Rate-Blood pressure-65
(CURB-65) score [5]. Recently, a new clinical prediction
rule for severe CAP, the severe community-acquired
pneumonia (SCAP) score, has been developed [6]. Few
studies have examined their performance in predicting
outcome of patients with HCAP [7].
The aim of this study was to compare PSI, CURB-65,
and SCAP scores for prediction of outcomes in a cohort of
patients with CAP and HCAP.
Methods
Setting and patients
This cohort study was performed prospectively in 59
divisions of internal medicine in 55 Italian hospitals [1].
An institutional review board of the Italian Society of
Internal Medicine (SIMI) approved the study. We classified
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patients as having HCAP if they had attended a hospital or
hemodialysis clinic or received intravenous chemotherapy
in the past 30 days, had been admitted to an acute-care
hospital for at least 2 days or had surgery in the past
180 days, or resided in a nursing home or long-term care
facility. CAP was defined as a diagnosis of pneumonia in
patients living in the community who did not meet any of
the criteria for HCAP. We stratified patients into risk
classes using the PSI [4], CURB-65 [5], and SCAP scores
[6]. This analysis was not designed in the original study
protocol, but is a post hoc analysis using prospectively
collected data. At the clinical end points, we retrieved the
variables of septic shock, need for transfer into an intensive
care unit (ICU), and in-hospital death.
Antimicrobial treatment evaluation
We defined empirical antibiotic therapy as antibiotics
administered on the first day of therapy for pneumonia. We
considered the antibiotic regimen as adherent to guidelines
if it was concordant with the available American Thoracic
Society and Infectious Diseases Society of America
guidelines for CAP and HCAP [8, 9]
Statistical analysis
Data are showed as mean [95% Confidence Intervals (CI)]
for quantitative variables and as relative frequencies (95%
CI) for categorical variables. We performed nonparametric
tests for group comparison and the generalized Fisher exact
test for contingency table analysis.
The Cox regression analysis was performed to find the
model that best predicted in-hospital death or the combined
outcome (septic shock, need of transfer into an ICU, and
in-hospital death) using fractional polynomial regression to
study relationships between independent quantitative vari-
ables and outcome. After univariate analysis, independent
variables at p value level of 0.20 were chosen and included
in the model with an afterward selection process. Clinical
variables already included in the three severity rules (PSI,
CURB-65, and SCAP score) were not further considered.
Finally, a cluster procedure was used to validate the best-fit
regression model and adjust standard errors for intragroup
correlation. Hazard ratios and their 95% CI were com-
puted. STATA/SE, version 9.2 for Windows (Stata Corp,
College Station, TX) was used to analyze the data.
Results
The sample included 313 patients with pneumonia, 223
(71.2%) classified as having a CAP and 90 (28.8%) as
having a HCAP. The two groups did not significantly differ
in terms of mean age, gender distribution, and presence of
comorbidities [1]. Table 1 summarizes some baseline
characteristics of patients with CAP and HCAP included in
the study. When compared to patients with CAP, HCAP
patients were less frequently included in low-risk classes of
PSI (23.3 vs 8.9%, p = 0.004), CURB-65 (43.9 vs 34.4%,
p = 0.01), and SCAP score (41.7 vs 23.3%, p = 0.004),
and less frequently treated with an empirical therapy that
was consistent with available guidelines (26.7 vs. 58.7%,
p \ 0.001). The overall mortality rate was 9.9%, and was
significantly higher in patients with HCAP (17.8%) than
with CAP (17.8 vs. 6.7%, p \ 0.01).
Differences in the proportion of in-hospital mortality in
each severity class, as assessed by PSI, CURB-65 and
SCAP score, are presented in Table 2. HCAP patients
included in the low class of the three severity rules had
Table 1 Baseline clinical characteristics of patients with CAP and
HCAP
CAP HCAP P
n = 223 n = 90
Respiratory rate [30 breaths/min 73 (32.8%) 31 (34.4%) 0.7
Systolic blood pressure \90 mmHg 6 (2.7%) 6 (6.7%) 0.1
Pulse [125/min 73 (32.7%) 35 (38.9%) 0.2
Altered mental status 44 (19.8%) 24 (26.7%) 0.3
Blood urea nitrogen [30 mg/dl 69 (30.9%) 40 (44.4%) 0.02
PaO2/FiO2 \ 300 59 (26.5%) 38 (42.2%) 0.01
Bilirubin [1.5 mg/dL 26 (11.7%) 13 (14.4%) 0.5
Hematocrit [30% 95 (42.6%) 60 (66.7%) <0.01
Glucose [250 mg/dl 34 (15.2%) 22 (24.4%) 0.07
Bold values are those statistically significant
Table 2 In-hospital mortality in each severity class assessed by PSI,
CURB-65 and SCAP scores in patients with CAP and HCAP
CAP HCAP P
PSI class
Low (I) 0 12.5 (0–36.6) 0.133
Intermediate (II) 4.6 (0.6–8.5) 11.1 (3.9–18.3) 0.157
High (III) 16.1 (7.7–24.6) 27 (13.9–40.1) 0.206
CURB-65 Class
Low (I) 3.1 (0–7.1) 12.9 (2.6.–23.2) 0.057
Intermediate (II) 10 (3.9–16.1) 12.5 (1.8–23.2) 0.742
High (III) 8.6 (0–18.6) 29.6 (12.2–47) 0.045
SCAP Class
Low (I) 2.1 (0–5.8) 9.5 (0–20.8) 0.154
Intermediate (II) 8.7 (2.8–14.7) 12.2 (3–21.4) 0.538
High (III) 12 (1.7–22.3) 32.1 (16–48-2) 0.039
Data are shown as percentage (95% CI)
Bold values are those statistically significant
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higher mortality rates (range 9.5–12.9%) than CAP ones
(range 0–3.1%).
Outcome of HCAP and CAP patients was also evaluated
in terms of cumulative incidence of adverse events,
including development of septic shock, transfer into an
ICU, and death. As described in Table 3, the incidence of
adverse events is significantly higher among HCAP
patients included in the low class of PSI (p = 0.01),
CURB-65 (p = 0.01), and SCAP score (p = 0.04). Among
HCAP patients, inclusion in the low-risk classes is not
associated with higher percentages of empirical antibiotic
therapy not adherent to international guidelines (data not
shown).
Results of the multivariate Cox regression analysis are
described in Tables 4 and 5. Inclusion in the severe classes
of PSI, CURB-65, and SCAP scores and receipt of an
empirical therapy not adherent to international guidelines
prove to be risk factors independently associated with
intra-hospital mortality or development of adverse events.
Discussion
This study has evaluated the performance of three severity
rules, PSI, CURB-65, and SCAP score, in predicting the
outcomes of patients with CAP and HCAP. We find no
significant differences regarding the cumulative incidence
of adverse events (death, septic shock, and need of transfer
into an ICU) in patients included in the severe classes of
the three scores. Cox regression analysis confirms that
inclusion in severe classes is a factor significantly associ-
ated with death or development of complications. How-
ever, in the low classes, the incidence of adverse events is
significantly higher in HCAP patients than in CAP ones.
Thus, the three severity rules fail to detect a considerable
amount of HCAP cases at increased risk of complicated
outcome.
Several studies suggest that HCAP should be considered
as a single clinical entity, different from CAP in terms of
clinical presentation and outcome [1–3]. Our HCAP
patients have a worse prognosis as compared to CAP
despite no significant differences in terms of mean age or
comorbid conditions between the two groups [1]. The poor
prognosis of HCAP patients is related to a greater severity
of disease (demonstrated by higher mean SOFA scores and
by more frequent bilateral and multilobar lung involve-
ment), and to the receipt of an initial antibiotic treatment
not recommended by international guidelines [1]. These
findings confirm previous studies alerting physicians to the
greater likelihood of HCAP patients to receive inappro-
priate initial antibiotic treatment and their greater risk of
in-hospital mortality [10]. Compared to CAP patients,
those with HCAP are reported as frequently infected by
MDR pathogens [2, 11]. This finding has been recently
confirmed by a sub-analysis of our published prospective
study, which shows a high frequency of S. aureus etiology
in the HCAP group (the rate of methicillin resistance is
63.6%) while S. pneumoniae predominates in the CAP
group [12]. Thus, a critical factor influencing the in-hos-
pital mortality is the receipt of an initial inappropriate
Table 4 Factors associated
with intra-hospital mortality as
assessed by multivariate Cox
regression analysis
Three models are showed using
each of the predictive score
systems; the first class was used
as reference
Bold values are those
statistically significant
Hazard ratio 95% CI P
CURB-65 class II 3.1 1.1–8.8 0.03
CURB-65 class III 3.7 1.3–10.8 0.01
Empirical therapy not adherent to guidelines 11.1 3.2–37.8 <0.001
PSI class II 2.9 1.4–11.7 0.28
PSI class III 6.7 1.2–36.9 0.03
Empirical therapy not adherent to guidelines 10.7 3.1–37.2 <0.001
SCAP class II 1.7 0.5–5.5 0.40
SCAP class III 3.4 0.9–12.2 0.06
Empirical therapy not adherent to guidelines 11.2 3.2–39.5 <0.001
Table 3 Cumulative incidence of adverse events (septic shock, ICU
transfer, and death) in each severity class assessed by PSI, CURB-65,
and SCAP scores in patients with CAP and HCAP
CAP HCAP P
PSI class
Low (I) 0 25 (0–51.9) 0.016
Intermediate (II) 7.3 (2.8–11.9) 15.5 (7.1–24) 0.139
High (III) 21 (12.4–29.5) 29.7 (16.6–42.8) 0.342
CURB-65 Class
Low (I) 3.1 (0–7.1) 16.1 (5.2.–27.1) 0.019
Intermediate (II) 11.1 (5–17.2) 15.6 (3.6–27.7) 0.536
High (III) 22.9 (7.1–38.7) 37 (18.8–55.2) 0.267
SCAP Class
Low (I) 2.1 (0–5.8) 14.3 (1.6–26.9) 0.043
Intermediate (II) 10 (3.7–16.3) 14.6 (4.5–24.8) 0.550
High (III) 22 (9.9–34.1) 39.3 (23–55.5) 0.122
Data are shown as percentage (95% CI)
Bold values are those statistically significant
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antibiotic therapy, a risk clearly higher in HCAP patient
where MDR pathogens are more frequently isolated.
Shindo et al. [11], using a scoring system proposed by
the Japanese Respiratory Society, find significant differ-
ences in the in-hospital mortality and occurrence of MDR
pathogens between HCAP and CAP patients included in
the moderate risk class, but not in the severe classes. In our
series, the three severity rules underestimate the risk of
death of HCAP patients included in the low-risk classes.
This finding may be related to a high incidence of MDR
pathogens in the low-risk classes. However, the lack of
extensive microbiological data confirms the need for new
studies focussed on microbiology and therapy of HCAP, to
recognize those patients with HCAP who are misdiagnosed
as having CAP, and thus treated initially with antibiotic
regimens that do not cover the causative pathogens.
In conclusion, our study demonstrates that PSI, CURB-
65, and SCAP score have a good performance in patients
with CAP but are less useful in patients with HCAP,
especially in patients classified in the low-risk classes. The
receipt of an initial antibiotic therapy not recommended in
the ATS/IDSA guidelines seems to be a crucial factor
associated with intra-hospital mortality or development of
adverse events. Future studies are needed to clarify if
implementation of international pneumonia treatment
guidelines is useful in improving the outcomes of hospi-
talized patients with HCAP.
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